LCAT and chronic kidney disease: In future studies, we will need to investigate the molecular mechanisms, whereby APOA4, LCAT, PON1, and PON3 protect against atherosclerosis in CKD and if improving their levels in HDL will reverse CKD atherosclerosis in model systems.